Airbus completes third medical supplies mission

0

Airbus is continuing its initiative of purchasing and supplying millions of face masks from China, the large majority of which will be donated to the governments of Airbus’s home countries of France, Germany, Spain and the UK.

On Sunday 5th April an Airbus flight test crew completed its latest supply mission with an A350-1000 test aircraft – the third such mission between Europe and China. The aircraft returned to France with a cargo of four million face masks.

The A350-1000 left Toulouse, France, on Friday 3 April, reaching the Airbus site in Tianjin, China on 4 April and returning to Hamburg the same day.

Since mid-March, the previous two missions were performed by and A330-800, and A330 Multi-Role Tanker Transport (MRTT). Airbus also deployed an A400M and its Beluga fleet to transport shipments of masks between its European sites, in France, Germany, the UK and Spain. 

The A350-1000 being loaded with masks at Tianjin, China

“I would like to pay tribute to all the Airbus teams, globally, supporting the fight against Covid-19. They’re living our values in assisting those who are saving lives every day”, said Guillaume Faury, CEO of Airbus.  

Airbus is also deploying its employees’ expertise and know-how, and leveraging technology in the fight against the Covid-19 pandemic, for example in designing and manufacturing ventilators and 3D-printed visors for hospitals.

Share this story:

About Author

mm

Ever since his first flight on a TriStar, Adam has loved air travel, and since becoming editor of the Aircraft Interiors International brand he has really enjoyed the opportunity to be involved with the latest aircraft and airline products before they are even launched. Adam co-ordinates the running of the magazine, from commissioning articles and artwork, to ensuring that high standards of quality are maintained, as well as managing online content. Adam is proud to sit on the jury of the Crystal Cabin Awards and to have laid on the bed in Etihad's Residence.

Comments are closed.